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ABSTRACT
BACKGROUND Aneurysms affecting the aorta are a common condition associated with high mortality as a result of
aortic dissection or rupture. Investigations of the pathogenic mechanisms involved in syndromic types of thoracic aortic
aneurysms, such as Marfan and Loeys-Dietz syndromes, have revealed an important contribution of disturbed trans-
forming growth factor (TGF)-b signaling.
OBJECTIVES This study sought to discover a novel gene causing syndromic aortic aneurysms in order to unravel the
underlying pathogenesis.
METHODS We combined genome-wide linkage analysis, exome sequencing, and candidate gene Sanger sequencing in a
total of 470 index cases with thoracic aortic aneurysms. Extensive cardiological examination, including physical exami-
nation, electrocardiography, and transthoracic echocardiography was performed. In adults, imaging of the entire aorta
using computed tomography or magnetic resonance imaging was done.
RESULTS Here, we report on 43 patients from 11 families with syndromic presentations of aortic aneurysms caused by
TGFB3 mutations. We demonstrate that TGFB3 mutations are associated with signiﬁcant cardiovascular involvement,
including thoracic/abdominal aortic aneurysm and dissection, and mitral valve disease. Other systemic features overlap
clinically with Loeys-Dietz, Shprintzen-Goldberg, and Marfan syndromes, including cleft palate, biﬁd uvula, skeletal over-
growth, cervical spine instability and clubfoot deformity. In line with previous observations in aortic wall tissues of patients
with mutations in effectors of TGF-b signaling (TGFBR1/2, SMAD3, and TGFB2), we conﬁrm a paradoxical up-regulation of
both canonical and noncanonical TGF-b signaling in association with up-regulation of the expression of TGF-b ligands.
CONCLUSIONS Our ﬁndings emphasize the broad clinical variability associated with TGFB3 mutations and
highlight the importance of early recognition of the disease because of high cardiovascular risk. (J Am Coll Cardiol
2015;65:1324–36) © 2015 by the American College of Cardiology Foundation.
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T he transforming growth factor (TGF)-bpathway plays an important role in manymedically relevant processes, including
immunologic maturity, inﬂammation, cancer, and
ﬁbrosis, as well as skeletal, vascular, and hematopoi-
etic homeostasis (1). With the discovery of dysregu-
lated TGF-b signaling in Fbn1 knockout mice, the
TGF-b pathway was revealed as a key player in the
pathogenesis of thoracic aortic aneurysm develop-
ment in Marfan syndrome (MFS; [Mendelian In-
heritance in Man (MIM) 154700]) (2,3). MFS is a
multisystemic disease characterized by cardiovascu-
lar, ocular, and skeletal features caused by mutations
in the FBN1 gene (4). More recently, we and others
identiﬁed pathogenic mutations in the genes encod-
ing the TGF-b receptor (TGFBR) subunits TGFBR1
and TGFBR2 (5,6), the signaling transducer SMAD3
(7), the ligand TGFB2 (8,9), and the inhibitor SKI
(10), occurring predominantly in patients with syn-
dromic presentations of thoracic aortic aneurysms
and dissections (TAAD), designated Loeys-Dietz syn-
drome (LDS1 [MIM 609192] [11]; LDS2 [MIM 610168]
[11]; LDS3 [MIM 613795] [also known as aneurysms-
osteoarthritis syndrome] [7,12,13], LDS4 [MIM 614816]
[8]), and Shprintzen-Goldberg syndrome (SGS
[MIM 82212]) (13,14). The ﬁnding of human mu-
tations in a ligand, receptors, a signaling trans-
ducer, and an inhibitor of the TGF-b pathway
conﬁrms the essential role of TGF-b signaling
in aortic aneurysm development.
Recently, de novo mutations in the gene
encoding the TGFB3 ligand (TGFB3) were re-
ported in 2 girls exhibiting a syndrome
affecting body growth (either short or tall
stature) accompanied by skeletal features
reminiscent of MFS or LDS, but without sig-
niﬁcant vascular involvement (15–17). Here,
we report that TGFB3 mutations cause a
syndromic form of aortic aneurysms and
dissections, characterized by cardiovascular,
craniofacial, cutaneous, and skeletal anoma-
lies that signiﬁcantly overlap with other TGF-b vas-
culopathies, particularly those within the LDS clinical
spectrum.
METHODS
PATIENTS. All patients or relatives provided written
informed consent for participation in this study and,
if applicable, publication of photographs. Family 1
SEE PAGE 1337
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was investigated by the department of Clinical
Genetics (Erasmus University Medical Center, Rot-
terdam, the Netherlands) and Center for Medical Ge-
netics (Antwerp University Hospital/University of
Antwerp, Belgium) after previous surgical inter-
ventions. Clinical geneticists (M.W.W., B.L.L.) exam-
ined family members, with special attention to
skeletal, joint, skin, and craniofacial features. Medical
records from deceased patients were obtained for re-
view. Extensive cardiological examination, including
physical examination, electrocardiography, and
transthoracic echocardiography, was performed. In
adults, imaging of the entire aorta using computed
tomography or magnetic resonance imaging was per-
formed. Measurements of the aortic diameter were
obtained at the level of the aortic annulus, sinuses of
Valsalva, sinotubular junction, proximal ascending
aorta, aortic arch, descending aorta, and suprarenal
and infrarenal abdominal aorta. An aneurysm was
deﬁned as an arterial diameter >1.96 SDs above the
predicted diameter (18,19). Probands from families 2
through 8 and 9 through 11 were referred for molecular
and/or clinical evaluation to Antwerp (Belgium) or
Osaka (Japan), respectively.
Screening of the entire coding region of TGFB3 was
performed in 470 additional probands (120 probands
had whole-exome sequencing), presenting both with
syndromic and nonsyndromic forms of TAAD. The
majority of these patients had been screened previ-
ously for all known TAAD genes. Family members of
mutation-positive patients were ascertained and
submitted to clinical investigations.
CENTRAL ILLUSTRATION The Pathway From Patient to Gene and Back
The ﬁgure summarizes how initial identiﬁcation of patients and families, followed by linkage and mutation analysis led to the discovery of TGFB3 mutations. Further
exploration of the TGF-b pathway allowed a better phenotypical delineation and characterization that will have implications in personalized clinical management.
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GENOTYPING AND LINKAGE ANALYSIS. Genomic
DNA was extracted from peripheral blood samples
(Gentra Systems, Qiagen, Hilden, Germany). RNA from
2 patients (1-II:12 and III:11) (Figure 1) was extracted
from peripheral blood (collected in PAXgene tubes,
PreAnalyliX, Qiagen) according to the manufacturer’s
protocol (PreAnalyliX, Qiagen).
Genome-wide genotyping was conducted using
DNA from 6 family members (Figure 1, family 1)
with Illumina Human SNP-Cyto12 Arrays (Illumina,
San Diego, California), containing >262,000 genomic
markers, as recommended by the manufacturer. The
statistical package, easyLINKAGE Plus v5.08 (20),
Merlin v1.0.1 software (Abecasis Lab, University of
Michigan), was used to perform single-point and
multipoint parametric linkage analysis as previously
described (21,22). Logarithm of odds scores were ob-
tained using a dominant model of inheritance, with
90% penetrance and disease allele frequency of
1:1,000. Allele frequencies of genotyped single nucle-
otide polymorphisms (SNPs) were set to codominant,
and spacing of 0.25 Mb to 0.15 Mb between SNPs was
used. Haplotype blocks containing 100 SNPs were
constructed with Merlin (option BEST) and they were
visualized using HaploPainter (v1.042, H. Thiele,
University of Cologne, Germany).
SEQUENCING AND MUTATION ANALYSIS. Exome
sequencing was performed for 120 patients after Tru-
Seq Exome enrichment on HiSeq (Illumina). In 350
other probands, bidirectional Sanger sequencing of
exons and exon–intron boundaries was undertaken
using polymerase chain reaction primers designed
by Primer3 software (v. 4.0.0, S. Rozen, Howard
HughesMedical Institute and theNational Institutes of
Health, National Human Genome Research Institute)
(Online Table 1). Polymerase chain reaction products
were puriﬁed and sequenced using BigDye Terminator
chemistry v3.1 on an ABI Prism3130xl (Applied Bio-
systems, Foster City, California). Sequences were
aligned (SeqScape v2.5 software, Applied Biosystems)
and compared with consensus sequences obtained
from the human genome databases (Ensembl and
NCBI). For annotation of DNA and protein changes,
the Mutation Nomenclature guidelines from the Hu-
man Genome Variation Society were followed (23).
To describe mutations at the cDNA level, the A from
the ATG start codon of the reference sequences
is numbered as 1 (mRNA NM_003239.2 and protein
NP_003230.1).
IN SILICO ANALYSIS OF NOVEL VARIANTS. The effects
of the mutations on protein structure and function
were predicted using SIFT BLink (v.5.2.2) and Muta-
tion Taster2. Population frequencies in controls
were obtained from dbSNP, Exome Variant Server
(EVS) (24), 1000Genomes (25), and Genome of the
Netherlands (26). To assess the putative effects
on splicing, the Splice Site Prediction by Neural
Network (27), the NetGene2 (28) and Alamut Soft-
ware Suite were used. Protein IDs used for conser-
vation were gij148342461 (ABQ59024.1), gij135685
(P17125.1), gij18266825 (P16047.2), gij135682 (P17247.1),
gij52138563 (NP_919367.2), gij410898023 (XP_003962498.1),
gij351050916 (CCD74236.1), gij17137520 (NP_477340.1),
gij135674 (P01137.2), and gij48429157 (P61812.1).
HOMOLOGY MODELING. A homology model was
built using the experimentally solved structure of
TGFB1 (PDB ﬁle [29] 3rjr, 60% identity) as a template.
The model was built using an automatic YASARA
script (30) with standard parameters. The model
contains a homodimer of residues 14 to 412.
IMMUNOHISTOCHEMISTRY. The protocol for staining
of formalin-ﬁxed, parafﬁn-embedded sections was
adapted from Baschong et al. (31) with modiﬁcations
(Detailed Methods, Online Appendix). Slides were
stained overnight at 4C with anti-pSmad2 antibody
(clone A5S, 1:100, Millipore, Billerica, Massachusetts)
and anti-pERK1/2 (clone D13.14.4E, 1:100, Cell Sig-
naling Technology, Danvers, Massachusetts) in 0.1%
Triton/TBS buffer, washed 3  10 min in Perm/
Staining buffer, and then stained with anti-rabbit
Alexa594 (Molecular Probes, Life Technologies,
Carlsbad, California) at 1:200 for 1 h at RT. Slides
were then washed 3  10 min in Perm/Staining buffer
and mounted with Hard Set VECTASHIELD Mounting
Media (Vector Laboratories, Burlingame, California)
with2-(4-amidinophenyl)-1H-indole-6-carboxamidine
(DAPI). Images were acquired on a Zeiss Axio-
Examiner (Carl Zeiss, Oberkochen, Germany) with
710NLO-Meta multiphoton confocal microscope at
25magniﬁcation.
IN SITU RNA WITH ACD RNASCOPE PROBES. The
ACD RNAscope probe Hs-TGFB1 probe (Advanced Cell
Diagnostics [ACD], Hayward, California) was used to
detect human TGFB1 transcript in conjunction with
the RNAscope 2.0 HD Reagent Kit (RED) from ACD
(Detailed Methods, Online Appendix).
HISTOLOGY. Slides were histologically examined af-
ter hematoxylin-eosin, Elastica van Gieson (elastin),
Alcian blue (proteoglycans), or Masson’s trichrome
(collagen) staining using standard techniques.
RESULTS
We studied a large Dutch family (family 1) with clin-
ical features overlapping with MFS and LDS consis-
tent with an autosomal dominant inheritance pattern.
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FIGURE 1 Overview of Families With TGFB3 Mutations
I:1 I:2
II:1
Fam 1: c.754+2T>C; p.Glu216_Lys251del
Fam 2: c.898C>T; p.Arg300Trp Fam 3: c.787G>C; p.Asp263His Fam 4: c.898C>T; p.Arg300Trp
Fam 7: c.1157delT; p.Leu386Argfs∗21Fam 6: c.1095C>A; p.Tyr365∗Fam 5: c.898C>T; p.Arg300Trp
Fam 8: c.1202T>C;
p.Leu401Pro
Fam 9: c.704delA; 
p.Asn235Metfs∗11
Fam 10: c.965T>C; 
p.Ile322Thr
Fam 11: c.898C>T;
p.Arg300Trp
I:1 I:2
II:1 II:2 II:3
III:3III:2III:1
I:1
I:1
I:2
I:2
II:1
II:1
II:2
III:2III:1
I:1 I:2
II:1 II:2
III:2III:1
II:1 II:2 II:3
I:2I:1
III:2III:1
+
++
+–
+
+
+
+ +
+ +
+
+
+
+
–
–
II:1 II:2 II:3 II:4 II:5 II:6 II:7
I:2I:1
III:11III:10III:9III:8
IV:3IV:2IV:1
III:7III:6III:5III:4III:3III:2III:1
+
+
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
I:2I:1
II:9 II:10 II:11 II:12 II:13 II:14 II:15 II:16
III:14III:13III:12III:11III:10III:9III:8
IV:3IV:2IV:1
III:7III:6III:5III:4III:3III:2III:1
+
+ +
+
+
+
+
– –
+
+
?
?
II:1 II:2 II:3
I:2I:1
+
––
––
II:1 II:2 II:3 II:4 II:5
I:2I:1
III:4III:3III:2III:1
+
II:1 II:2 II:3
I:2I:1
III:2III:1
+
The causal TGFB3 mutation is shown for each family. Probands are indicated with an arrow. Circle: female; square: male; open symbol: unaffected; solid symbol:
affected; diagonal line: deceased; brackets: adopted; question mark: clinical affection status unknown. Plus and minus signs indicate presence or absence of a TGFB3
mutation, respectively.
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Seven family members, between 40 and 68 years
of age, presented with aneurysms and dissec-
tions, mainly involving the descending thoracic and
abdominal aorta (Figure 1, Online Table 2). Three pa-
tients died from aortic dissection and rupture of the
descending thoracic or abdominal aorta (1-II:4, II:5,
and II:7) (Figure 1), conﬁrmed by autopsy in 2 cases
(1-II:4, age 57 years and II:5, 56 years). In addition,
4 members had mitral valve abnormalities, ranging
from mild prolapse to severe regurgitation requiring
surgical intervention. Craniofacial abnormalities
were rather subtle, including a long face, high-arched
palate, and retrognathia (Figure 2). Pectus deformity
and scoliosis were frequently observed (Figure 2).
Other recurrent ﬁndings included velvety skin, vari-
ces, and hiatal hernia. Several family members
presented with autoimmune features including (HLA-
B27 positive) spondyloarthritis, Graves’ disease, and
celiac disease.
Sequencing of all known TAAD genes (ACTA2,
COL3A1, EFEMP2, FBN1, FLNA, MYH11, MYLK,
NOTCH1, PRKG1, SKI, SLC2A10, SMAD3, TGFB2,
TGFBR1, TGFBR2) failed to identify a causal muta-
tion. Linkage analysis using SNP genotypes from
FIGURE 2 Phenotypic Characteristics of Patients With a TGFB3 Mutation
Observed clinical features include: long face (1-III:11, 5-II:1, 7-II:1, 8-II:1); pectus carinatum (1-IV:2); hypertelorism (2-III:7, 2-IV:2, 2-IV:3, 7-II:1,
8-II:1); biﬁd uvula (2-III:7, 2-IV:3, 7-II:1); joint hypermobility (2-IV:2); arachnodactyly (5-II:1); and metatarsus adductus (8-III:1). All affected
individuals or parents gave permission to publish these photographs.
J A C C V O L . 6 5 , N O . 1 3 , 2 0 1 5 Bertoli-Avella et al.
A P R I L 7 , 2 0 1 5 : 1 3 2 4 – 3 6 TGFB3 Mutations Cause Aortic Aneurysms
1329
6 patients of the family identiﬁed 2 large geno-
mic regions on chromosomes 14 and 15 shared by
all affected patients (Online Figure 1). Detailed in-
spection of the genes in the regions identiﬁed several
candidates, most prominently the TGFB3 gene on
14q24. Subsequent Sanger sequencing of all 7 exons
and intron boundaries identiﬁed a heterozygous
intronic variant affecting the highly conserved
(PhastCons: 1, PhyloP: 4.97) canonical donor splice
site of exon 4 (c.754þ2T>C), which is absent
from variant databases (Variant Server, Genome
of the Netherlands, 1000Genomes). Sequencing of
the cDNA for 2 patients (1-II:12 and III:11) con-
ﬁrmed skipping of exon 4, leading to an in-frame
deletion of 108 nucleotides (Online Figure 2). At the
protein level, a deletion of 36 amino acids is ex-
pected (p.Glu216_Lys251del). This TGFB3 mutation
(c.754þ2T>C) segregated with the clinical phenotype
and was also present in 1 young individual (1-IV:1,
17 years old) without documented cardiovascular
features (Figure 1, Online Table 2), but with mild
systemic manifestations including craniofacial fea-
tures, easy bruising, and scoliosis.
To further investigate the role of TGFB3 in TAAD
etiology, DNA samples from 350 syndromic and non-
syndromic TAAD probands were Sanger sequenced
for mutations in all exon–intron boundaries and
the coding region of TGFB3. Additionally, in 120
TAAD patients, a targeted analysis of TAAD candi-
date genes after whole-exome sequencing was per-
formed. This revealed additional heterozygous TGFB3
mutations in 10 other probands (7 from Sanger
sequencing and 3 from the exome sequencing co-
hort): 4 different missense mutations, p.Asp263His
(family 3), p.Arg300Trp (families 2, 4, 5, 11),
p.Ile322Thr (family 10), p.Leu401Pro (family 8); 1
nonsense mutation, p.Tyr365* (family 6); and 2
single-base deletions leading to a frameshift and
premature stop codon, p.Leu386Argfs*21 (family 7)
and p.Asn235Metfs*11 (family 9) (Figure 3). All
FIGURE 3 Mutation Overview of the TGFB3 Gene
Untranslated region
c.899G>A°
p.Arg300Gln
c.1226G>A°°
p.Cys409Tyr
Signal peptide
LAP domain
TGFB3 cytokine domian
c.704delA
p.Asn235Metfs∗11
c.754+2T>C
p.Glu216_Lys251del
c.787G>C
p.Asp263His
26
3
H. Sapiens TGFB3
H. Sapiens TGFB1
H. Sapiens TGFB2
M. Musculus tgfb3
G. Gallus tgfb3
D. Rerio tgfb3
F. Rubripes tgfb3
C. Elegans tgfb3
D. Melanogaster tgfb3
c.898C>T
p.Arg300Trp (X4)
30
0
32
2
40
1
c.965T>C
p.Ile322Thr
c.1202T>C
p.Leu401Pro
c.1095C>A
p.Tyr365∗
c.1157delT
p.Leu386Argfs∗21
5’UTR 3’UTR1 2 3 4 5 6 7
Exons are represented by rectangles. Exon numbering is given, and different colors denote the different protein domains. Mutations found in
this study are indicated below the gene in the respective domains. Evolutionary conservation in TGFB3 and its related proteins is given for the
4 missense mutations (p.Arg300Trp: Family 2, 4, 5 and 11; p.Asp263His: Family 3; p.Leu401Pro: Family 8; p.Ile322Thr: Family 10). Previously
published mutations are shown above the gene, with a single degree symbol indicating mutation described in Matyas et al. (17) and double
degree symbols indicating mutation from Rienhoff et al. (16).
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missense mutations were predicted as deleterious
by SIFT (32) and as disease causing by Mutation
Taster (33). The 2 missense mutations in exon 5
(p.Asp263His and p.Arg300Trp) both affect highly
conserved amino acids of the latency-associated
peptide (LAP) domain, which are also conserved
among the TGFB1, TGFB2, and TGFB3 proteins
(Figure 3). The p.Asp263His alteration disrupts the
Arg-Gly-Asp (RGD) motif, which is essential for
binding to the avß3, avß6, avß1, and avß5 integrins
(34–36). Mutations of the RGD motif in LAPb3 were
demonstrated to abolish binding to avß3, avß5, and
avß6 (36). The second missense mutation in exon 5,
p.Arg300Trp, affects the last amino acid of the LAP
domain, disrupting the last residue of the RKKR
minimal recognition motif of the furin or related
protease cleavage site (37). Mutations affecting
similar amino acids in TGFB2 have been shown to
be causal in syndromic forms of aortic aneurysms
(8). The 2 other missense mutations, p.Ile322Thr
and p.Leu401Pro, affect highly conserved amino
acids located in the region of the active cytokine.
The 3 other mutations create premature stop co-
dons, either in the LAP domain or in the active
TGFB3 (cytokine) domain, leading to nonsense-
mediated decay or truncated proteins, which prob-
ably lose their cytokine activity.
The causal nature of the TGFB3 mutations was
further supported by de novo occurrence (family 6)
(Figure 1) and absence from controls (all mutations)
in EVS, 1000Genomes, and the Genome of the
Netherlands. Although p.Tyr365* in family 6 occurred
de novo, we previously identiﬁed a SMAD3 variant
(p.Ala250Thr) of unknown signiﬁcance in the pro-
band. This SMAD3 variant was also present in the
proband’s mother, who presented with variable con-
nective tissue ﬁndings and mild cardiovascular
involvement, making its precise contribution to
pathogenesis unclear.
We studied the molecular effects of these
mutations in more detail using a homology model
of the TGFB3 dimer. Asp263 is located in a sur-
face loop where it is accessible for integrins
(Figure 4). Mutation p.Glu216_Lys251del results in
deletion of a central beta-strand and subsequent
surface loop in the LAP domain (Figure 4). This
will severely affect this domain’s conformation,
including the position of the RGD motif, and
thereby affect dimerization and inhibition of the
TGFB3 domain.
Missense mutations p.Arg300Trp, p.Ile322Thr, and
p.Leu401Pro are also predicted to alter TGFB3 func-
tion. Besides participating in the cleavage site,
Arg300 is involved in several ionic interactions that
will be lost with the substitution to tryptophan,
and this bulky residue will likely induce steric rear-
rangements. Ile322Thr is predicted to alter the
positioning of Arg325, an important amino acid res-
idue for binding with TGFBR2. In addition, hydro-
phobic contacts with the N-terminal helix in the LAP
domain will be affected by the substitution with
threonine (hydrophilic). Substitution from Leu401
to proline is predicted to change the hydrophobic
interactions with residues of both the LAP and
TGFB3 domain.
The clinical phenotypes in the 10 additional
families demonstrate signiﬁcant overlap with Loeys-
Dietz syndrome (Online Tables 3 to 6). Vascular
involvement ranges from no cardiovascular abnor-
malities at age 64 (3-II:2) to type A (median age of
51 years, range 40 to 80 years) or type B aortic
dissection (median age of 44.5 years, range 30 to 57),
abdominal aortic dissection and death as a result
of cerebral aneurysm dissection at age 55 (2-II:1)
(Table 1). So far, no examples of early arterial
FIGURE 4 Overview of the TGFB3 Dimer Model and Mutations
Asp263His
Arg300Trp
Leu401Pro
Ile322Thr
One monomer is shown in grey, with the other monomer in cyan (LAP domain) and
blue (TGFB3 domain). Residues deleted by the p.Glu216_Lys251del mutation are in
purple. Residues affected by the p.Leu386Argfs21* mutation are in yellow (note that
this mutation also adds 21 different residues that cannot be modeled). Residues deleted
by the p.Tyr365* mutation are shown in orange and yellow (note that this mutation
deletes all residues following Tyr365). Residues deleted by mutation p.Asn235Metfs*11
are shown in grey-olive in the second monomer (note that this mutation also adds 11
different new residues, which cannot be modeled). The point mutations p.Asp263His,
p.Arg300Trp, p.Ile322Thr, and p.Leu401Pro are shown in red with their side chains
visible as red spheres. A detailed close-up of these mutations is shown in 4 extra
panels. In these panels, the wild-type residue side chain is in green, whereas the
mutant side chain is in red. For the p.Arg300Trp mutation, side chains of nearby
negative residues are also shown. For the p.Leu401Pro mutation, nearby hydrophobic
residues are shown.
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dissection or dissection at small aortic dimension
were observed. Other cardiovascular features include
mitral valve disease, ranging from mild insufﬁciency
to chorda rupture necessitating surgery, and persis-
tent foramen ovale and atrial or ventricular septal
defects. Disease beyond the aorta, with iliac and
subclavian artery aneurysms, was only identiﬁed in
2 patients (1-II:12 and 1-III:13). No striking aortic or
arterial tortuosity was observed.
Typical LDS ﬁndings such as hypertelorism, biﬁd
uvula and cleft palate, cervical spine instability, and
club foot deformity are commonly observed (Figure 2,
Tables 1, 2, and Online Tables 3 to 6). Other recurrent
features include dolichocephaly, high-arched palate,
retrognathia (with surgery in case 3-III:1), tall stature,
joint hypermobility, arachnodactyly, pectus defor-
mity, and inguinal hernia (Table 1, Figure 2). No
evidence for ectopia lentis was found in the medical
records. Early-onset osteoarthritis was only reported
in 2 individuals (10-II:1 and 11-II:1). The clinical
features from 43 identiﬁed patients belonging to 11
families are summarized in Table 1. We observed a
striking intrafamilial and interfamilial clinical vari-
ability with typical LDS features in some, but com-
plete absence in others.
We subsequently investigated the effect of the
p.Asp263His mutation on aortic wall architecture
and TGF-b signaling. Microscopic examination of
the dissected aortic wall, obtained at the time of
surgery (3-III:1), showed elastic ﬁber fragmentation
with higher collagen and proteoglycan deposition
(Figures 5A to 5C). These histopathological ﬁndings
are highly reminiscent of both MFS and LDS (8).
Retrieved pathology reports from 2 patients (1-II:4
and II:5) carrying the p.Glu216_Lys251del mutation
(family 1) also described extensive elastic ﬁber frag-
mentation with “pseudo cyst formation” in the
medial layer of the dissected aorta and “aortic medial
degeneration.” In families 9 and 10, only mild elastic
ﬁber fragmentation was observed.
To investigate TGF-b signaling in the aortic wall of
a patient carrying a TGFB3 mutation (p.Asp263His),
we performed immunohistochemical analysis of
aortic tissue (Figures 5D to 5F). Very similar to what
has been detected in TGFB2-deﬁcient aortic walls
of humans and mice (8), we observed evidence of
paradoxically enhanced TGF-b signaling in the aortic
wall of a TGFB3 mutant patient, as shown by in-
creased pSMAD2 (canonical TGF-b signaling), pERK
(noncanonical TGF-b signaling), and elevated TGFB1
messenger RNA (Figures 5D to 5F).
DISCUSSION
During mouse embryonic development, Tgfb3 is
expressed in several tissues, including cardiovas-
cular, pulmonary, skin, and craniofacial structures.
TABLE 2 Comparison of Phenotypical Characteristics of Patients
With TGFBR1/2, SMAD3, TGFB2, and TGFB3 Mutations
Phenotype
TGFBR1
TGFBR2 SMAD3 TGFB2 TGFB3
Hypertelorism U U U U
Biﬁd uvula/cleft palate U U U U
Exotropia U U U U
Craniosynostosis U U  
Cervical spine instability U U  U
Retrognathia surgery U U U U
Scoliosis/spondylolisthesis U U U U
Clubfoot U U U U
Osteoarthritis U U  U
Dural ectasia U U U ?
Pneumothorax U U U 
Hernia U U U U
Dissection at young age U U U ?
Disease beyond root U U U U
Cerebral hemorrhage U U U U
Arterial tortuosity U U U 
Autoimmune ﬁndings U U U U
A check mark indicates presence of the clinical feature, an X indicates absence of
the clinical feature, and a question mark indicates presence of a clinical feature is
unknown.
TABLE 1 Patient Characteristics
Affected Individuals (n ¼ 43)*
Sex, M/F 23/20
Age, yrs 34 (3–74)
Age at death, yrs 56 (40–80)
Age at dissection, yrs 47.5 (30–80)
Cardiovascular ﬁndings
Type A dissections, age, yrs 4 (51; 40–80)
Type B dissections, age, yrs 6 (44.5; 30–57)
Aortic aneurysm†, age, yrs 6 (34; 3–68)
Abdominal aortic surgery‡ 2
Disease beyond aorta§ 3
Skeletal ﬁndings
Tall stature 12
Arachnodactyly 16
Pectus deformity 8
Kyphoscoliosis 11
Joint hypermobility 9
Loeys-Dietz features
Hypertelorism 14
Biﬁd uvula 11
Cleft palate 5
Values are n, median (range), or n (median; range). *Not all patients were
evaluated for all features. †Four aneurysms affected the sinuses of Valsalva, and 2
only affected the ascending aorta. ‡Surgery was performed on 1 patient at
age 43 years and 1 at 50 years. §Cerebral, iliac, or subclavian arteries (n ¼ 1 for
each location).
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FIGURE 5 Cardiovascular Pathology and Immunohistochemical Analysis of TGFB Family Proteins in a Human Subject With TGFB3 Mutation (3-III:1; p.Asp263His)
(A) Masson trichrome staining shows increased deposition of collagen (dark blue) and loss of smooth muscle ﬁbers (red) in the media. (B) Elastin stain (Elastica van
Gieson) shows loss of elastin ﬁbers (black). (C) Hematoxylin-eosin staining shows deposition of proteoglycan (light blue) in the media. (A–C) Scale bar indicates 2 mm.
(D–F) Cross sections of the media of the aortic wall of patient 3-III:1 and a matched control. Red staining corresponds to pSmad2 (D); pERK (E); and TGFB1 (F). Scale bars
indicate 50 mm (D–E), 20 mm (F). Blue staining shows cell nuclei (DAPI), colocalization is purple. Red staining not colocalized with DAPI is nonspeciﬁc.
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Although Tgfb3 is expressed in overlapping fashion
with Tgfb2 in the cardiovascular system, most
attention has been paid to its role in palatogenesis,
as Tgfb3 knockout mice die at birth because of cleft
palate (38,39). No major cardiac developmental
defects have been reported in Tgfb3-deﬁcient mice
(38,40,41). Although minor abnormalities at the
aortic arch level, as well as in position and curva-
ture of the aortic arches and myocardial architec-
ture, were described in the Tgfb3 knockout mice,
no data are available on the aortic sizes of con-
ditional knockout or haploinsufﬁcient animals
(39,40). Of interest, the presence of aortic aneu-
rysms and ruptures recapitulating the human
phenotype were previously overlooked upon the
initial phenotypic description of Tgfb2 hap-
loinsufﬁcient and Smad3 knockout mouse models
(8,30).
Because we observed 3 truncating mutations and
an in-frame splice site mutation, we hypothesize
that the TGFB3 mutations lead to loss of function
(LOF) of TGFB3. In addition, 2 missense mutations,
located in the LAP domain, alter critical residues
that are relevant for TGFB3 activation by integrins
and TGFB3 processing (35,42). Mice carrying a
missense mutation affecting the RGD integrin-
binding motif of Tgfb1 recapitulate the phenotype
of Tgfb1 knockout mice (43), suggesting that the
TGFB3 mutation disrupting the RGD (p.Arg263His)
might also lead to LOF. Similarly, molecular ana-
lyses and predictions based on the TGFB3 dimer
model conﬁrm that most TGFB3 mutations reported
here cause LOF. Although it was previously hy-
pothesized that patients with LOF mutations in
TGFB3 lack cardiovascular phenotypes (16), we
clearly demonstrate that TGFB3 LOF mutations
associate with aortic and other arterial aneurysms/
dissections and mitral valve disease, and recognize
an extremely variable cardiovascular phenotype in
the TGFB3 cohort described here. The relatively
young age of previously reported patients with
TGFB3 mutations (8 [16] and 10.5 years of age
[17]) might explain the lack of obvious cardiovas-
cular disease. On the basis of expression studies
of the mutant TGFB3 protein in a Xenopus
model, Rienhoff et al. (16) hypothesized that the
mutated, inactivated allele (p.Cys409Tyr) leads to a
nonfunctional protein, decreasing both canonical
and noncanonical TGF-b signaling. By contrast, our
experiments on human aortic tissue reveal a signa-
ture of increased TGF-b signaling. These ﬁndings
conﬁrm our prior experience that mutational hits in
the TGFBR1/2 receptors, the SMAD3 signal trans-
ducer, or the TGFB2 ligand lead to a paradoxical
increase in TGF-b signaling, as evidenced here
by increased immunohistochemical signals for
pSMAD2, pERK, and TGFB1 (5,7,8). Shifts in bal-
ances between canonical (pSMAD2) and non-
canonical (pERK) cascades, classic, and alternative
(BMP-driven) TGF-b superfamily cascades, as well
as shifts in ligand expression (TGFB1 vs. TGFB2
or TGFB3) seem likely to be important contributing
factors (44,45).
TGFB3 mutations also appear to have opposing
effects on height, as 1 patient in this study (3-
III:1, p.Asp263His) has short stature and received
growth hormone therapy during puberty, and
the patient reported by Rienhoff et al. (16)
(p.Cys409Tyr) presented with short stature (5th
percentile), whereas others (several patients in this
study and the patient reported by Matyas et al.
[17]) presented with tall stature. TGFB3 mutations
affecting residue Arg300 are associated with cleft
palate and/or biﬁd uvula in our patients (Online
Tables 3, 4, and 6) and in the patient reported
by Matyas et al. (17). Our study conﬁrms the as-
sociation of TGFB3 mutation with overt cleft pal-
ate in humans and endorses its important role in
palatogenesis.
Although our experience is limited to 43 patients
in 11 families, our ﬁndings warrant comprehensive
cardiovascular imaging of the patients. Thus far,
no strong evidence has emerged for early aortic
dissection in TGFB3 mutant patients, but as the
phenotypical spectrum associated with TGFBR1/2,
SMAD3, and TGFB2 has now been demonstrated
to be extremely wide, we cannot rule out the
occurrence of early catastrophic events. We rec-
ommend yearly echocardiographic evaluation of
the aortic root in all mutation carriers, com-
plemented with at least 1 baseline imaging of the
complete aorta and side branches. Frequency of
follow-up should be guided by initial ﬁndings, fam-
ily history, and experience still to be gained.
Depending on family history and future knowledge,
additional imaging of the brain vessels might be
indicated. Furthermore, the true incidence and
full spectrum of autoimmune manifestations in
TGFB3 mutation carriers should be determined in
follow-up studies.
STUDY LIMITATIONS. Not all clinical features are
acquired in all patients. Further studies are needed to
fully characterize the phenotypical spectrum we
identiﬁed here. The predicted effects of the muta-
tions in the homology model of TGFB3 are theoretical
and should be complemented with additional protein
studies, and the immunohistochemistry studies are
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hampered by limited availability of patients’ aortic
wall tissues.
CONCLUSIONS
We demonstrate that mutations in the TGFB3 ligand
are responsible for a syndromic form of aortic aneu-
rysmal disease. Consistent with our previous ﬁndings
in TGFBR1/2, SMAD3, and TGFB2 mutation carriers,
our study also provides evidence for a paradoxical
increase in TGF-b signaling in the aorta. The clinical
histories of the patients in our cohort warrant life-
long and widespread cardiovascular surveillance in
patients with TGFB3 mutations (Central Illustration).
Further research explaining the wide clinical vari-
ability is strongly indicated.
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